Acurx Pharmaceuticals

Company snapshot

Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. We have discovered and developed three proprietary technology platforms to address abuse and misuse across multiple fronts. • Limitx™ Technology is designed to retard the release of active drug ing

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 28 US patent(s) indexed to this assignee profile.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Acurx Pharmaceuticals. Not investment advice.

• Peer + 0 momentum

  Finch Therapeutics Group

  TA overlap score 21

Recent activity

Latest pipeline, patent, and corporate events for Acurx Pharmaceuticals.

1. Jun 5, 2026 Clinical update

   Ibezapolstat — Phase 2

2. Jun 5, 2026 Clinical update

   Ibezapolstat — Phase 2

3. Jul 16, 2024 Patent grant

   Use of ibezapolstat to promote microbiome health

4. Jan 2, 2024 Patent grant

   Methods and compositions for self-regulated release of active pharmaceutical ingredient

5. Aug 15, 2023 Patent grant

   Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse

View all clinical trial activity →

• What is Acurx Pharmaceuticals?

  Acura Pharmaceuticals is a pharma organization headquartered in Palatine, USA. It trades on NYSE under ticker ACXP. Primary therapeutic focus areas include Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence. NovaPharmaNews links 2 clinical program(s), 0 d

• Is Acurx Pharmaceuticals publicly traded?

  Yes. Acurx Pharmaceuticals is listed with ticker ACXP on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Acurx Pharmaceuticals develop or market?

  We link 1 drug profile(s) where Acurx Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/acurx-pharmaceuticals#company-drugs.

• What are the latest developments for Acurx Pharmaceuticals?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Acurx Pharmaceuticals focus on?

  Acurx Pharmaceuticals focuses on Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence based on our analysis of their pipeline programs and drug development activities.